Friday, April 19, 2019

IBM Watson Health cuts back Drug Discovery 'artificial intelligence' after lackluster sales - The Register

IBM Watson Health cuts back Drug Discovery 'artificial intelligence' after lackluster sales  The Register

IBM Watson Health is tapering off its Drug Discovery program, which uses "AI" software to help companies develop new pharmaceuticals, blaming poor sales.